Về Arensia exploratory medicine gmbh

Về công ty

The pharmaceutical companies are eager to obtain maximum information from fewer clinical trials at early stage. This enables quicker “go/no-go” decision for the development strategy of a given compound. The landscape of early clinical development has dramatically changed over the last years. The amount of Phase 1 studies in healthy volunteers has decreased, being replaced by Phase 1b/2a studies in patients.